HDAC2 and neoplasm: The results demonstrated that HDAC2 overexpression promoted tumor growth and compromised cisplatin-induced growth inhibition, and treatment with the HDAC inhibitor Entinostat reversed HDAC2-mediated cisplatin resistance.